Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.
I am deeply humbled by the decades of support from people around the world. It is an honor to share this painful yet ...
A phase 1/2 trial of a novel viral vector gene therapy in adults with type 1 diabetes is scheduled to begin this year.
A groundbreaking gene therapy tested through a UCLA-led clinical trial has received approval from the U.S. Food and Drug ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket has announced that the FDA signed off on an accelerated approval for its ...
Gene therapy for sickle cell disease shows strong clinician support but faces barriers in referral practices, knowledge, and insurance approval.
Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for ...
A groundbreaking gene therapy trial has successfully restored hearing in individuals with a rare form of congenital deafness.
RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
Peripheral nerve injuries, often caused by traumatic events such as car accidents, falls or battlefield injuries, can leave patients with long-term weakness, numbness or loss of function. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results